For instance, the pilot clinical trial NCT02802098 is seeking to explore the efficacy of combining the anti-PD-L1 durvalumab plus the antiangiogenic bevacizumab after bevacizumab monotherapy for advanced HER2-negative BC [152]. The gene discussed is ERBB2; the disease is breast cancer.